THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $9.0 million prior to deducting underwriting discounts and commissions and offering expenses.

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure

THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will release a Virtual Investor “What This Means” segment on Wednesday, October 30, 2024.

Live webcast on Wednesday, July 24^th at 4:00 PM ET

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company’s ongoing human clinical trial

Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman

Company plans to release topline results from “lead-in” patients (n=5) imminently

Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system

Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass

Live webcast on Thursday, May 16^th at 4:00 PM ET